Fractyl Health (NASDAQ:GUTS) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Fractyl Health (NASDAQ:GUTS) issued its quarterly earnings data on Monday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08), Zacks reports.

Fractyl Health Price Performance

NASDAQ:GUTS opened at $1.50 on Wednesday. Fractyl Health has a 52 week low of $1.37 and a 52 week high of $10.18. The firm has a market cap of $72.15 million and a price-to-earnings ratio of -0.12. The firm’s 50-day simple moving average is $1.76 and its 200 day simple moving average is $2.28. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58.

Insider Buying and Selling

In related news, insider Jay David Caplan sold 22,346 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the transaction, the insider now directly owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. This trade represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Harith Rajagopalan sold 90,972 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.82, for a total transaction of $165,569.04. Following the transaction, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $894,218.78. This represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analysts Set New Price Targets

Separately, Morgan Stanley dropped their price objective on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.